Sandeep Sahay, MD
Pulmonary Disease · Houston, TXNPI 1669602710
Payments from drug & device makers
Across 867 payments — averaging $2366.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$1.2M
- Sumitomo Pharma America, Inc.$233K
- Janssen Research & Development, LLC$221K
- Merck$216K
- Actelion Pharmaceuticals US, Inc.$85K
- Bayer$64K
- plus $69K from 17 others
Across 16 payments — averaging $159.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$3K
What the payments were for
- Consulting fees$194,21951%
- Speaking & faculty fees$116,53231%
- Travel & lodging$46,94412%
- Food & beverage$20,5505%
- Education$2270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 363 | $1,164,275 |
| Sumitomo Pharma America, Inc. | 7 | $232,501 |
| Janssen Research & Development, LLC | 19 | $220,895 |
| Merck | 166 | $215,872 |
| Actelion Pharmaceuticals US, Inc. | 168 | $85,066 |
| Bayer | 64 | $63,602 |
| Biogen | 3 | $57,210 |
| Enzyvant Therapeutics, Inc. | 1 | $6,504 |
| Boehringer Ingelheim | 19 | $2,714 |
| Bayer Healthcare LLC | 1 | $915 |
| Actelion Pharmaceuticals, Ltd | 9 | $787 |
| Liquidia Technologies, Inc. | 5 | $253 |
| GSK | 10 | $221 |
| Genentech USA, Inc. | 6 | $216 |
| Insmed, Inc. | 8 | $172 |
| Sandoz | 8 | $169 |
| Gilead | 4 | $74 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Sanofi | 1 | $21 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Grifols USA, LLC | 1 | $19 |
| AbbVie | 1 | $19 |
| Inogen, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,051,563 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 660 | $8,365,691 |
| UptraviSelexipag | 273 | $6,207,414 |
| AdempasRiociguat | 393 | $5,345,485 |
| Tyvaso DpiTreprostinil | 109 | $2,588,157 |
| Orenitram ErTreprostinil Diolamine | 133 | $1,958,241 |
| LetairisAmbrisentan | 67 | $1,056,203 |
| WinrevairSotatercept-Csrk | 54 | $838,759 |
| OfevNintedanib Esylate | 57 | $754,996 |
| Ambrisentan | 107 | $350,025 |
| Tadalafil | 281 | $337,510 |
| EsbrietPirfenidone | 28 | $322,293 |
| Tyvaso Refill KitTreprostinil/Neb Accessories | 14 | $286,274 |
| OpsynviMacitentan/Tadalafil | 17 | $213,410 |
| AdcircaTadalafil | 14 | $80,540 |
| Pirfenidone | 35 | $64,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $85,066 | $14,786,514950 claims |
| BayerAdempas | $63,602 | $5,345,485393 claims |
| GileadLetairis | $74 | $1,056,20367 claims |
| MerckWinrevair | $215,872 | $838,75954 claims |
| Boehringer IngelheimOfev | $2,714 | $754,99657 claims |
| Genentech USA, Inc.Esbriet | $216 | $322,29328 claims |
| United Therapeutics CorporationAdcirca | $1,164,275 | $80,54014 claims |
| GSKTrelegy Ellipta | $221 | $23,48127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
- Tara BartoHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.